In a recent paper in BMT, McDonough et al 1 reported their results with transplantation of CD34 þ augmented elutriated allografts in children. An important finding was that patients with nonmalignant diseases had a remarkably high risk for graft failure. Our own experience was different in such patients, 2 and we believe that an analysis of the differences between both therapeutical approaches may be of interest. The study of McDonough et al comprised 40 children with leukemias and 14 children with nonmalignant diseases (thalassemia, severe combined immunodeficiency (SCID), adrenoleukodystrophy (ALD), Fanconi anemia, congenital pancytopenia and autoimmune disease). The patients had received T-cell depleted bone marrow from matched related (n ¼ 18), mismatched related (n ¼ 10), matched unrelated (n ¼ 20) and one antigen mismatched unrelated donors (n ¼ 6). Counter flow centrifugal elutriation followed by CD34 þ selection (Ceprate system) of the elutriated small lymphocyte fraction was used for graft manipulation. A mean number of 4.7 Â 10 6 CD34 þ cells/ kg of body weight and 6.3 Â 10 5 residual T cells/kg of bodyweight were transplanted. In patients with nonmalignant diseases, the authors stated a clearly higher incidence of graft failure (8/14 patients, 57%). Four out of eight patients could be rescued by DLIs or a second BMT. The authors conclude that, for children with nonmalignant diseases, it will be necessary to increase the immune ablation of the preparative regimen and/or to improve post transplant immune suppression in order to prevent graft failure.
In our patients, a lower incidence of graft failure was observed. A similar patient group with various nonmalignant diseases (severe aplastic anemia, thalassemia, sickle cell disease, Diamond-Blackfan anemia, SCID, WiskottAldrich syndrome, ALD, osteopetrosis, porphyria, polycythemia vera rubra and lymphohistiocytosis) has been transplanted with purified CD34 þ stem cells in our institution. 2 Four patients had matched related donors and 21 patients had unrelated or mismatched related donors. In contrast to McDonough et al, stem cell selection was carried out in our study with anti-CD34 mAb-coated magnetic microbeads (Miltenyi Biotec). Moreover, G-CSFstimulated apheresis products were used instead of bone marrow. With this approach, a median number of 12.9 (3.4-40) Â 10 6 CD34 þ /kg bodyweight could be obtained for transplantation, which was markedly higher than the amount of stem cells (Table 1) . Moreover, chimerism was assessed weekly in peripheral blood samples and low doses of donor T cells (starting at 2.5 Â 10 4 /kg) were given to patients who showed decreasing donor chimerism, in order to maintain stable engraftment without causing GvHD.
Graft failure occurred in four out of 25 patients (16%). Three of those patients were successfully regrafted (with reconditioning and stem cells from the original donor, n ¼ 2; with reconditioning and stem cells from a mismatched related donor after a MUD graft had been rejected, n ¼ 1). Thus, only one patient had final nonengraftment. GvHD could be effectively minimized (grade II: 8%; grade III-IV: 0% compared to 19% GvHD II-IV reported by McDonough et al), which appears to be the major advantage of such graft manipulations. The overall mortality in our group with nonmalignant diseases was 12% compared to 50% in the respective group reported by McDonough et al. Therefore, our intensified conditioning seemed not to increase transplant-related toxicity. It has to be mentioned that McDonough et al found a favorable rate of graft failure in patients with malignant diseases (2/40, 5%). In a retrospective analysis of our patients with leukemias transplanted from unrelated and haploidentical donors (n ¼ 70), 16% graft failure was observed (here, all patients were successfully regrafted). 3, 4 However, the incidence of graft failure was only 4% (1/26) in patients who received stem cell doses higher than our current thresholds (X10 Â 10 6 CD34 þ cells from unrelated donors and X20 Â 10 6 CD34 þ cells from haploidentical donors) (unpublished results). In our opinion, this finding under- lines the importance of high stem cell doses in order to overcome HLA disparities and to counterbalance the low T-cell content of our grafts. We conclude that, in our experience, GvHD prophylaxis by CD34 þ selection is beneficial especially in patients with nonmalignant diseases. We agree with the statement of McDonough et al that conditioning regimens containing immunosuppressive agents like ATG may be necessary. However, our results suggest that high stem cell doses may be necessary as well to achieve acceptable engraftment rates also in those patients with probably more intact immunity or multiple pretransplant transfusions. Other helpful factors may be the avoidance of any post transplant immune suppression and the use of small T-cell addbacks in case of decreasing donor chimerism.
P Lang
R Handgretinger J Greil P Bader M Schumm T Klingebiel D Niethammer
